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Introduction
Articular cartilage is composed of chondrocytes and 
matrix, and it is difﬁ  cult for cartilage to heal after injury. 
In 1743, Hunter had stated that, “cartilage once 
destroyed is never recovered.”
1 This was true until 2003, 
when Koshino and colleagues reported regeneration of 
degenerated articular cartilage after high tibial valgus 
osteotomy for medial compartmental osteoarthritis of 
the knee.
2 In their report, 47 (32.2%) of 146 knees were 
totally covered by new regenerated ﬁ  brocartilage  or 
hyaline cartilage. Histology also demonstrated hyaline 
cartilage regeneration on previously degenerated medial 
femoral condyle. However, the regeneration occurred 
in only one-third of the knees. Many other treatments 
have also been used directly on focal lesions of 
the articular cartilage of the knee, including abrasion 
arthroplasty,
3 microfracture,
4 autogenous chondrocyte 
implantation,
5 allogenous osteochondral transplanta-
tion,
6 and autogenous osteochondral transplantation 
(“mosaicplasty”).
7
Johson
3 reported a 77% success rate at a 2-year 
follow-up for abrasion arthroplasty, although the 5-year 
follow-up success rate decreased to 51%–53%. The dis-
advantage of this technique is that abrasion may produce 
thermal necrosis. In contrast, Steadman et al.
4 used a 
microfracture technique that increased the stiffness of 
the bone and produced no heat necrosis, thus preserv-
ing the subchondral bone plate. After penetration of the 
bone plate, continuous passive motion was used for 6–8 
weeks with limited weight bearing. This yielded a 75% 
success rate after 7 years of follow-up.
Autogenous chondrocyte implantation (ACI) was 
reported in 1994. At a 2-year follow-up, 87% good to 
excellent results were reported in femoral lesions,
8 but 
patellar lesions tended to have a worse outcome. Peter-
son et al.
9 reported that at 2–9 years of follow-up good 
results were obtained in 92% of isolated femoral condyle 
lesions, 65% of patellar lesions, and 67% of multifocal 
chondral damage using ACI. The disadvantages of ACI 
include loss of phenotype in monolayer culture and 
leakage of cell suspension when injecting it into focal 
lesions that had been covered by periosteum during 
the repair procedures. Uneven distribution of cells is 
another shortcoming.
10
Allogenous osteochondral transplantation has been 
used, especially for sports injury,
6 and 60%–88% good/
excellent results have been reported at 4.5–7.8 years of 
follow-up.
11,12 Transmission of diseases and immune 
rejection
13 are pitfalls of the technique. Autogenous 
osteochondral transplantation was used by Hangody et 
al.
7 to treat focal osteochondral defects. Among 57 
patients, 91% good to excellent results were noted after 
3 years of follow-up. The disadvantage of this technique 
is poor integration of cartilage between the recipient 
site and chondral graft and hypertrophy of the chondral 
graft, which resulted in an irregular joint surface.
Based on these previous disadvantages, tissue engi-
neering of cartilage emerged, and biotechnology of 
stem cells and scaffolds has progressed rapidly in recent 
years.
14
Development of an ideal scaffold
We have used gelatin, hyaluronic acid, and chondroitin-
6-sulfate, a tricopolymer, to mimic the matrix of carti-
lage. Gelatin had been used for hemostasis during 
surgery. Hyaluronic acid is a nonsulfated glycoamino-
glycan (GAG) in the matrix of cartilage. Chondroitin-
6-sulfate appears to promote more diffuse chondrogenesis 
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and matrix production when combined with collagen II 
than when combined with collagen I.
15 The tricopoly-
mer has a uniform pore size of about 180  μm and 
adequate porosity of 75%.
16
When porcine chondrocytes were seeded into the tri-
copolymer for 4 weeks, newly secreted matrix with 
lacunar formatting around chondrocytes could be seen 
with Alcian blue staining. Based on the technology of 
stem cell and scaffolding, allogenous chondrocytes were 
cultivated in the tricopolymer to repair osteochondral 
defects in minipigs. Several ﬁ  ndings are worth mention-
ing
17: (1) Spontaneous healing as the defect ﬁ  lled with 
scaffolding alone did not result in good repair. (2) The 
subchondral bone plate was not restored in osteochon-
dral defects by engineered cartilaginous tissue. (3) Full-
thickness cartilage defects in an articular surface could 
be repaired by engineered cartilaginous tissue using the 
tricopolymer as a scaffold.
Because the tricopolymer mentioned above has not 
been approved for use in the human body, we have used 
atelocollagen, which has been used in humans by Kusaka 
et al. since 1987.
18–21 Ochi and colleagues cultivated 
autologous chondrocytes in thin scaffolds for 21–26 
days before transplantation onto the articular surface of 
the knee to repair defects caused by trauma and osteo-
chondritis dissecans, among other etiologies. At a 
follow-up of more than 25 months, the gross appearance 
was excellent. The hardness of the implanted site was 
similar to that of the surrounding cartilage.
22
Wakitani and colleagues were the ﬁ  rst to transplant 
human autologous stem cells into defects in osteoar-
thritic knees.
23 At 40 weeks after transplantation, the 
defects were covered with white soft tissue in which 
metachromasia was observed in almost all of the 
sampled tissue, and there was some hyaline cartilage-
like tissue as well. Since 2005, we have been cultivating 
mesenchymal stem cells (MSCs) in atelocollagen with 
or without transforming growth factor beta (TGFβ) for 
repairing full-thickness cartilage defects. The MSCs 
were size-sieved from bone marrow
24 and proved to be 
multipotent.
25 Preliminary results (reported at the 2007 
Congress of Tissue Engineering and Regenerative Med-
icine — International Society) showed that the cartilagi-
nous tissue induced from MSC by TGFβ could certainly 
repair full-thickness cartilage defects, as did the pure 
MSCs, although subchondral bone could not be restored 
by the induced MSCs.
26
Investigations in humans
Before tissue-engineered bioproducts are implanted 
into the human body, two basic conditions should be 
fulﬁ  lled: First, all bioproducts should be manufactured 
in good manufacturing practice (GMP) laboratories. 
Second, all reagents used for production should be 
hand-inspected by health authorities. Finally, a well-
designed protocol is necessary. Jakobsen et al.
27 sug-
gested six guidelines.
1. Studies should be prospective with a clearly deﬁ  ned 
hypothesis and have a clearly deﬁ  ned primary end-
point; and they should be randomized controlled 
trials. Secondary endpoints are used only as support-
ive evidence.
2. Patient inclusion and exclusion criteria should be 
clearly established and reported. The recruitment 
rate should be reported.
3. The outcome measure should be validated for use in 
patients with cartilage injuries.
4. Outcome should be assessed by an independent 
investigator.
5. The timing of the outcome assessment should be 
clearly stated.
6. Detailed rehabilitation protocols should be estab-
lished and reported.
We are fortunate to have a good tissue practice (GTP) 
cell manufacturing facility at the Biomedical Engineer-
ing Research Laboratories in the Industrial Technology 
Research Institute, Shinchu, Taiwan. At the time the 
paper was proofed, three patients with osteonecrosis of 
the medial femoral condyle had been treated by us 
with cartilage tissue induced from autologous MSCs. 
We expect that the results will be as good as those of 
mosaicplasty without its disadvantages, such as having 
a gap between the recipient site and the implant.
According to the slogan of the Orthopaedic Research 
Society of the United States, “Tomorrow’s treatments 
begin with today’s research.” Thus, the research 
on tissue engineering of cartilage will continue to 
progress.
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